Full-Time

Senior Clinical Study Manager

Clinical Operations

Posted on 9/3/2025

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$133.8k - $178.8k/yr

+ Bonus + Incentive Compensation Plan + Equity Awards

Remote in USA

Remote

Candidates must be based in the US.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Google Cloud Platform
Requirements
  • 6 or more years of progressive experience in clinical research within biotech, pharma or CRO industry
  • Proven experience in clinical research including relevant experience as team lead in clinical functions
  • Experience as CRA is preferred
  • MS Office, Project Planning Applications
Responsibilities
  • Accountable for regional study delivery with appropriate inspection readiness quality, within agreed timelines and budget
  • Acts as regional lead for multiple studies across an indication or across a program as required
  • Leads the regional clinical operations team (including external partners working on a regional level) and acts as point of escalation for resolution of issues within the region for the assigned study
  • Ensures alignment of regional deliverables with overall study goals
  • Contributes to the development of regional tools and leads the development of work instructions and SOPs as required
  • Leads planning and management of the assigned clinical study(ies) from feasibility through closeout activities for region, in line with global study timelines
  • Generates, manages, and maintains high quality study start up and recruitment timelines for region and tracks progress towards these
  • Ensures that the clinical study is operationally feasible in the region, drives trial feasibility, country allocation and site selection process for assigned region in collaboration with feasibility managers, country heads, medical affairs and any other stakeholders
  • Provides regional input on global study plans as required
  • Ensures timely availability of local adaptations of global study documents such as informed consent forms, in close collaboration with other key stake holders to ensure timely submission to regulatory authorities and ECs/IRBs
  • Accountable for submissions of study in countries in assigned region in close collaboration with regional study start up team and regulatory affairs
  • Ensures regional and country information in study systems and tools is entered and up to date
  • Collaborates closely with CRAs in the region to ensure proper study execution at the sites. Reviews and signs-off monitoring reports
  • Responsible for working with regional and country teams to ensure that country and site level Trial Master File is created, maintained and QC’d on a regular basis as per the study TMF QC plan
  • Provides input to Global Clinical Supplies regarding drug inventories in region and reviews local drug labels for region. Provides input on local regulatory approval and reimbursement status of comparator drugs used in study for countries in region
  • Manages the trial data collection process for the region, drives data entry and query resolution
  • As required, supports planning and execution of the Clinical Study Report in collaboration with Global Clinical Study Manager and Medical Writing
  • Handles escalated issues or problems with the sites in region in close collaboration with stakeholders such as country heads
  • Monitors study activities in region to ensure compliance with study protocol, SOPs, ICH/GCP and all other relevant regulations
  • Ensures inspection readiness for study in region at any point in time throughout the study life cycle
  • Informs Global Clinical Study Manager of any issues arising on the study, evaluates impact and ensures solutions are implemented
  • Prepares sites for quality assurance audits and inspections, drives responses to audit and inspection findings as appropriate
  • Collaborates with CST members and other colleagues to ensure cross-team, site learnings, and best practices are shared
  • Leads improvements and partners with CST members to enhance the efficiency and the quality of the work performed on assigned studies
  • Leads the development, optimization and review of work instructions and SOPs as required
  • Works with the sourcing team to select and manage regional study vendors
  • Manages regional study budgets
  • Works closely with Clinical Business Operation on investigator fees, site payment issues and patient travel reimbursement activities
  • Identifies and manages regional team resource needs and establishes contingency plans for key resources
  • Monitors regional resource utilization over study life cycle and liaises with functional managers as needed
  • Provides performance feedback on team members as required
  • Mentors junior team members and might take on line management responsibilities as required
Desired Qualifications
  • Higher Degree preferred

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • TEVIMBRA Priority Review and Breakthrough Designation for HER2+ gastric cancer expands addressable market.
  • Q1 2026 revenue of $1.5B exceeds forecasts; BRUKINSA sales grew 38% year-over-year.
  • First GAAP profitability achieved in 2025 with $942M free cash flow generation.

What critics are saying

  • AbbVie's ABBV-599 Phase 3 readout H2 2026 directly challenges BRUKINSA's CLL dominance.
  • Merck's pembrolizumab FDA label expansion blocks TEVIMBRA's gastric cancer approval pathway.
  • Dr. Reddy's ibrutinib generic captures 15% CLL market share with 25% price discounts.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL versus competitors.
  • Only BTK inhibitor showing superiority versus ibrutinib in head-to-head clinical trials.
  • Advanced ADC platform with multispecific antibodies and proprietary payload chemistry for tumor targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE